These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 27172372)

  • 1. Is HPV vaccination in pregnancy safe?
    Bonde U; Joergensen JS; Lamont RF; Mogensen O
    Hum Vaccin Immunother; 2016 Aug; 12(8):1960-1964. PubMed ID: 27172372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
    Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
    Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of quadrivalent human papillomavirus vaccine (Gardasil) in pregnancy: adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006-2013.
    Moro PL; Zheteyeva Y; Lewis P; Shi J; Yue X; Museru OI; Broder K
    Vaccine; 2015 Jan; 33(4):519-22. PubMed ID: 25500173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of the HPV Bivalent and Quadrivalent Vaccines During Pregnancy.
    Forinash AB; Yancey AM; Pitlick JM; Myles TD
    Ann Pharmacother; 2011 Feb; 45(2):258-62. PubMed ID: 21285408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tracking the global spread of vaccine sentiments: the global response to Japan's suspension of its HPV vaccine recommendation.
    Larson HJ; Wilson R; Hanley S; Parys A; Paterson P
    Hum Vaccin Immunother; 2014; 10(9):2543-50. PubMed ID: 25483472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is administration of the HPV vaccine during pregnancy feasible in the future?
    Berenson AB; Patel PR; Barrett AD
    Expert Rev Vaccines; 2014 Feb; 13(2):213-9. PubMed ID: 24308583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial.
    Gilca V; Sauvageau C; Panicker G; De Serres G; Ouakki M; Unger ER
    Vaccine; 2018 Nov; 36(46):7017-7024. PubMed ID: 30314913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
    Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
    Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse events following HPV vaccination, Alberta 2006-2014.
    Liu XC; Bell CA; Simmonds KA; Svenson LW; Russell ML
    Vaccine; 2016 Apr; 34(15):1800-5. PubMed ID: 26921782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Inadvertent 9-Valent Human Papillomavirus Vaccine in Pregnancy With Spontaneous Abortion and Adverse Birth Outcomes.
    Kharbanda EO; Vazquez-Benitez G; DeSilva MB; Naleway AL; Klein NP; Hechter RC; Glanz JM; Donahue JG; Jackson LA; Sheth SS; Greenberg V; Panagiotakopoulos L; Mba-Jonas A; Lipkind HS
    JAMA Netw Open; 2021 Apr; 4(4):e214340. PubMed ID: 33818618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse pregnancy outcomes and infant mortality after quadrivalent HPV vaccination during pregnancy.
    Faber MT; Duun-Henriksen AK; Dehlendorff C; Tatla MK; Munk C; Kjaer SK
    Vaccine; 2019 Jan; 37(2):265-271. PubMed ID: 30503078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peri-conceptional or pregnancy exposure of HPV vaccination and the risk of spontaneous abortion: a systematic review and meta-analysis.
    Tan J; Xiong YQ; He Q; Liu YM; Wang W; Chen M; Zou K; Liu XH; Sun X
    BMC Pregnancy Childbirth; 2019 Aug; 19(1):302. PubMed ID: 31426762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of spontaneous abortion and other pregnancy outcomes in 15-25 year old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom.
    Baril L; Rosillon D; Willame C; Angelo MG; Zima J; van den Bosch JH; Van Staa T; Boggon R; Bunge EM; Hernandez-Diaz S; Chambers CD
    Vaccine; 2015 Nov; 33(48):6884-91. PubMed ID: 26206268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials.
    Wacholder S; Chen BE; Wilcox A; Macones G; Gonzalez P; Befano B; Hildesheim A; Rodríguez AC; Solomon D; Herrero R; Schiffman M;
    BMJ; 2010 Mar; 340():c712. PubMed ID: 20197322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience.
    Angelo MG; Zima J; Tavares Da Silva F; Baril L; Arellano F
    Pharmacoepidemiol Drug Saf; 2014 May; 23(5):456-65. PubMed ID: 24644078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: Interim analysis of a large community-randomized controlled trial.
    Lehtinen M; Eriksson T; Apter D; Hokkanen M; Natunen K; Paavonen J; Pukkala E; Angelo MG; Zima J; David MP; Datta S; Bi D; Struyf F; Dubin G
    Hum Vaccin Immunother; 2016 Dec; 12(12):3177-3185. PubMed ID: 27841725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.
    Romanowski B; Schwarz TF; Ferguson L; Peters K; Dionne M; Behre U; Schulze K; Hillemanns P; Suryakiran P; Thomas F; Struyf F
    Hum Vaccin Immunother; 2016; 12(1):20-9. PubMed ID: 26176261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine.
    Garland SM; Cheung TH; McNeill S; Petersen LK; Romaguera J; Vazquez-Narvaez J; Bautista O; Shields C; Vuocolo S; Luxembourg A
    Vaccine; 2015 Nov; 33(48):6855-64. PubMed ID: 26411885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maternal and infant outcomes following exposure to quadrivalent human papillomavirus vaccine during pregnancy.
    Bukowinski AT; Hall C; Chang RN; Gumbs GR; Marie S Conlin A
    Vaccine; 2020 Aug; 38(37):5933-5939. PubMed ID: 32712082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme.
    Angelo MG; David MP; Zima J; Baril L; Dubin G; Arellano F; Struyf F
    Pharmacoepidemiol Drug Saf; 2014 May; 23(5):466-79. PubMed ID: 24644063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.